The bioavailability and disposition kinetics of genistein in cats

N. J. Cave, R. C. Backus, Stanley L Marks, K. C. Klasing

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.

Original languageEnglish (US)
Pages (from-to)327-335
Number of pages9
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume30
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Genistein
genistein
Biological Availability
bioavailability
Cats
cats
mouth
kinetics
dosage
half life
Isoflavones
isoflavones
intravenous injection
Intravenous Administration
oral administration
Oral Administration
Half-Life
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

The bioavailability and disposition kinetics of genistein in cats. / Cave, N. J.; Backus, R. C.; Marks, Stanley L; Klasing, K. C.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 30, No. 4, 08.2007, p. 327-335.

Research output: Contribution to journalArticle

Cave, N. J. ; Backus, R. C. ; Marks, Stanley L ; Klasing, K. C. / The bioavailability and disposition kinetics of genistein in cats. In: Journal of Veterinary Pharmacology and Therapeutics. 2007 ; Vol. 30, No. 4. pp. 327-335.
@article{c41f625086ba41fdae09abd06cc7f9d4,
title = "The bioavailability and disposition kinetics of genistein in cats",
abstract = "The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9{\%} (free) and 29.85 ± 22.61{\%} (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.",
author = "Cave, {N. J.} and Backus, {R. C.} and Marks, {Stanley L} and Klasing, {K. C.}",
year = "2007",
month = "8",
doi = "10.1111/j.1365-2885.2007.00868.x",
language = "English (US)",
volume = "30",
pages = "327--335",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The bioavailability and disposition kinetics of genistein in cats

AU - Cave, N. J.

AU - Backus, R. C.

AU - Marks, Stanley L

AU - Klasing, K. C.

PY - 2007/8

Y1 - 2007/8

N2 - The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.

AB - The absorption and disposition kinetics of the soy isoflavone genistein were determined in cats (n = 6). An oral dose of 100 mg/kg was administered, which has previously been demonstrated to be the minimum oral estrogenic dose, and was administered intravenously at a dose of 20 mg/kg, being the largest practical dose that could be safely administered. Plasma free, and total (conjugated + free) genistein concentrations were determined by HPLC following organic extraction. Noncompartmental analysis revealed a half-life of 21.67 ± 7.9 h (free) and 9.95 ± 2.7 h (conjugated), volume of distribution 31.94 ± 10.38 L/kg (free) and 11.82 ± 3.96 L/kg (conjugated) following intravenous administration. Following oral administration the half-lives were determined to be 17 ± 4.8 h (free) and 8.56 ± 4.65 h (conjugated), with tmax = 4.4 ± 0.6 h (free) and 4.42 ± 0.99 h (conjugated), and Cmax = 0.276 ± 0.1 μg/mL (free) and 6.24 ± 6.58 μg/mL (conjugated). Oral bioavailabilities were 1.379 ± 0.9% (free) and 29.85 ± 22.61% (conjugated). The ratio of total:free genistein ranged from 25.9 to 5.5. Poor oral absorption and efficient conjugation explain the low bioavailability of free genistein. Accumulation of genistein in peripheral lipophilic compartments may occur.

UR - http://www.scopus.com/inward/record.url?scp=34347400398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347400398&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2885.2007.00868.x

DO - 10.1111/j.1365-2885.2007.00868.x

M3 - Article

VL - 30

SP - 327

EP - 335

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 4

ER -